DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for thanatophoric dysplasia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleThanatophoric dysplasia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for thanatophoric dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 3 (FGFR3) — FGFR3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4K33 · 2.3405 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER (ACP). Experimental structure, not a prediction.
What the evidence adds up to
Thanatophoric dysplasia is a lethal skeletal dysplasia characterised by marked underdevelopment of the skeleton and short-limb dwarfism. Anatomical features include a short neck, narrow thoracic cage, protuberant abdomen, relatively enlarged head with frontal bossing, prominent eyes, hypertelorism, and a depressed nasal bridge. The condition is divided into two clinically defined subtypes: thanatophoric dysplasia type 1 and type 2. Type 1 features curved femur and flattened vertebral bodies; both subtypes involve severe limb shortening, a severely small thorax, large head with prominent forehead, and macrocephaly. The syndrome is usually lethal in the perinatal period.
Diagnosis is typically made by ultrasonography in the second trimester. At the first trimester, the traditional sonographic signs are rarely seen. Thanatophoric dysplasia is often associated with increased nuchal translucency at first-trimester screening, but it may not be clearly distinguished from other skeletal dysplasias at that stage. A definite diagnosis can be established by molecular genetic analysis.
No drug treatments, clinical trials, or therapeutic interventions for thanatophoric dysplasia are described in these reports. The literature reviewed consists entirely of case reports and diagnostic imaging studies. No survival data, response rates, or sample sizes from treatment studies are available because none were conducted.
What is still missing is any preclinical or clinical research into pharmacological intervention, including drug repurposing. There are no trials, no patient stratification strategies, and no funding directed toward treatment development for this condition. The published work remains confined to prenatal diagnosis and anatomical description.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Oman Medical Journal · 2011 · 35 citations · open access
Thanatophoric Dysplasia: A Rare Entity
AbstractThanatophoric dysplasia is the lethal skeletal dysplasia characterized by marked underdevelopment of the skeleton and short-limb dwarfism. The child will be having a short neck, narrow thoracic cage and protuberant abdomen. Other anatomical features include a relatively enlarged head with frontal bossing, prominent eyes, hypertelorism and the depressed nasal bridge. The diagnosis is usually made with the ultrasonography in the second trimester. In this study we report a case of this rare entity with emphasis on its anatomical features, abnormalities and clinical profile with relevant review of literature.
International Journal of Reproduction Contraception Obstetrics and Gynecology · 2014 · 1 citations · open access
Thanatophoric dysplasia type 1 (TD1): a case report
AbstractThanatophoric Dysplasia (TD) is a severe short-limb dwarfism syndrome that is usually lethal in the perinatal period. It is characterized by shortening of the limbs, severely small thorax, large head with a prominent forehead, macrocephaly, curved femur, and flattened vertebral bodies. Thanatophoric dysplasia is divided into 2 clinically defined subtypes: thanatophoric dysplasia type 1 & type 2 (TD1 & TD2). We report this case because of its rarity with review of literature.
Thanatophoric dysplasia: possibilities of early prenatal ultrasound diagnosis
AbstractWe reviewed cases of early prenatal diagnosis of thanatophoric dysplasia (TD). Usually ТD is diagnosed at ultrasonic in the second-trimester scan. At first trimester the sonographic traditional signs of TD meet rarely. Often TD to be associated with increased nuchal translucency at first-trimester screening. TD may not be clearly distinguished from the other skeletal dysplasias in a first trimester. A definite diagnosis can be established by molecular genetic analysis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
